Skip to main content
Fig. 5 | Molecular Cancer

Fig. 5

From: MARCKSL1–2 reverses docetaxel-resistance of lung adenocarcinoma cells by recruiting SUZ12 to suppress HDAC1 and elevate miR-200b

Fig. 5

MARCKSL1–2 epigenetically inhibits HDAC1 expression by recruiting SUZ12 to HDAC1 promoter. a-b The impact of SUZ12 on the mRNA and protein levels of HDAC1 assessed by RT-qPCR and Western blot in indicated LAD cells. c-d ChIP assay plus AGE or RT-qPCR was used to evaluate the enrichment of HDAC1 promoter in SUZ12 groups. e ChIP assay analyzed the impact of SUZ12 on the H3K27me3 modification at HDAC1 promoter in indicated LAD cells. f-g ChIP assay was conducted to evaluate the changes in enrichment of HDAC1 promoter recognized by SUZ12 in SPC-A1/H1299 cells with MARCKSL1–2 inhibition and in DTX-resistant LAD cells with MARCKSL1–2 upregulation. h The influence of MARCKSL1–2 silence or overexpression on the level of H3K27me3 modification at HDAC1 promoter assessed by ChIP experiments. **P < 0.01

Back to article page

Molecular Cancer

ISSN: 1476-4598